Current
State and Perspectives of Diabetes Research:
Chronic Complications
Foreword
P.J. DYCK
S3
Approaches to improve
epidemiological studies of diabetic neuropathy:
insights from the
Rochester Diabetic Neuropathy Study (RDNS)
P.J. DYCK, L.J. MELTON, III, P.C.
O'BRIEN, AND F.J. SERVICE
S5
Endothelial dysfunction: cause of
the insulin resistance syndrome
J.H. PINKNEY, C.D.A. STEHOUWER,
S.W. COPPACK, AND J.S. YUDIN
S9
Antioxidant defense: vitamins E
and C and carotenoids
W. STAHL AND H. SIES
S14
Recent progress in advanced
glycation end products and diabetic complications
H. VLASSARA
S19
Growth factor alterations in
advanced diabetic retinopathy: a possible role of
blood retina barrier breakdown
A. PFEIFFER, J. SPRANGER, R.
MEYER-SCHWICKERATH, AND H. SCHATZ
S26
Metabolic and vascular factors in
the pathogenesis of diabetic neuropathy
N.E. CAMERON AND M.A. COTTER
S31
The roles of oxidative stress and
antioxidant treatment in experimental diabetic
neuropathy
P.A. LOW, K.K. NICKANDER, AND H.J.
TRITSCHLER
S38
Role of neurotrophins in diabetic
neuropathy and treatment with nerve growth
factors
D.R. TOMLINSON, P. FERNYHOUGH, AND
L.T. DIEMEL
S43
The pathology of human diabetic
neuropathy
R.A. MALIK
S50
Classification, differential
diagnosis, and staging of diabetic peripheral
neuropathy
P.K. THOMAS
S54
The pathogenesis of diabetic foot
problems: an overview
J.E. SHAW AND A.J.M. BOULTON
S58
 -lipoic acid in the treatment of
diabetic peripheral and cardiac autonomic
neuropathy
D. ZIEGLER AND F.A. GRIES
S62
Diagnosis of cardiovascular
autonomic neuropathy in diabetes
V. SPALLONE AND G. MENZINGER
S67
Pathophysiology of diabetic
gastroparesis
P. ENCK AND T. FRIELING
S77
Aldose reductase inhibitors: the
end of an era or the need for different trial
designs?
M.A. PFEIFER, M.P. SCHUMER, AND
D.A. GELBER
S82
Essential fatty acids in the
management of impaired nerve function in diabetes
D.F. HORROBIN
S90
Upright posture and the
microvasculature in human diabetic neuropathy: a
hypothesis
J.D. WARD
S94
Pathogenesis of diabetic vascular
disease: evidence for the role of reduced heparan
sulfate proteoglycan
T. JENSEN
S98
Blood glucose control and
microvascular and macrovascular complications in
diabetes
K.F. HANSSEN
S101
How to protect the kidney in
diabetic patients: with special reference to IDDM
C.E. MOGENSEN
S104
Role of modified lipoproteins in
diabetic macroangiopathy
J.L. WITZTUM
S112
Blood vessel wall interactions in
diabetes
K. SCHROR
S115
Impaired coronary flow reserve in
NIDDM: a possible role for diabetic cardiopathy
in humans
B.E. STRAUER, W. MOTZ, M. VOGT,
AND B. SCHWARTZKOPFF
S119
The role of nutritional
modifications in the prevention of macrovascular
complications of diabetes
J.I. MANN
S125
Pharmacological strategies to
prevent macrovascular disease in NIDDM
J.A. COLWELL
S131
|
